Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2005 1
2007 1
2008 1
2010 1
2011 2
2012 4
2013 1
2014 3
2016 1
2017 3
2018 6
2019 4
2020 2
2021 6
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Venous thromboembolism.
Khan F, Tritschler T, Kahn SR, Rodger MA. Khan F, et al. Among authors: rodger ma. Lancet. 2021 Jul 3;398(10294):64-77. doi: 10.1016/S0140-6736(20)32658-1. Epub 2021 May 10. Lancet. 2021. PMID: 33984268 Review.
After completing 3-6 months of initial treatment, anticoagulation can be discontinued in patients with venous thromboembolism provoked by a major transient risk factor. Patients whose long-term risk of recurrent venous thromboembolism outweighs the long-term risk of …
After completing 3-6 months of initial treatment, anticoagulation can be discontinued in patients with venous thromboembolism provoked by a …
Pulmonary embolism.
Huisman MV, Barco S, Cannegieter SC, Le Gal G, Konstantinides SV, Reitsma PH, Rodger M, Vonk Noordegraaf A, Klok FA. Huisman MV, et al. Among authors: rodger m. Nat Rev Dis Primers. 2018 May 17;4:18028. doi: 10.1038/nrdp.2018.28. Nat Rev Dis Primers. 2018. PMID: 29770793 Review.
Future research should aim to address novel treatment options (for example, fibrinolysis enhancers) and improved methods for predicting long-term complications and defining optimal anticoagulant therapy parameters in individual patients, and to gain a greater understanding …
Future research should aim to address novel treatment options (for example, fibrinolysis enhancers) and improved methods for predicting long …
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
EINSTEIN–PE Investigators; Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. EINSTEIN–PE Investigators, et al. N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26. N Engl J Med. 2012. PMID: 22449293 Free article. Clinical Trial.
CONCLUSIONS: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. ...
CONCLUSIONS: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of …
Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
Rodger MA, Le Gal G. Rodger MA, et al. Blood Adv. 2018 Nov 13;2(21):3081-3087. doi: 10.1182/bloodadvances.2018020230. Blood Adv. 2018. PMID: 30425073 Free PMC article. Review.
In most scenarios, which are faced on a day-to-day basis in routine practice, it is a challenging decision because of uncertainty in estimates in the long-term risks (principally major bleeding) and benefits (reducing recurrent VTE) and the tight trade-offs between them. . …
In most scenarios, which are faced on a day-to-day basis in routine practice, it is a challenging decision because of uncertainty in estimat …
Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
Rodger MA, Le Gal G. Rodger MA, et al. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):426-431. doi: 10.1182/asheducation-2018.1.426. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504342 Free PMC article. Review.
In most scenarios, which are faced on a day-to-day basis in routine practice, it is a challenging decision because of uncertainty in estimates in the long-term risks (principally major bleeding) and benefits (reducing recurrent VTE) and the tight trade-offs between them. . …
In most scenarios, which are faced on a day-to-day basis in routine practice, it is a challenging decision because of uncertainty in estimat …
Treatment of venous thromboembolism.
Wells PS, Forgie MA, Rodger MA. Wells PS, et al. Among authors: rodger ma. JAMA. 2014 Feb 19;311(7):717-28. doi: 10.1001/jama.2014.65. JAMA. 2014. PMID: 24549552 Review.
OBJECTIVE: To review the etiology of VTE and the 3 phases of VTE treatment: acute (first 5-10 days), long-term (from end of acute treatment to 3-6 months), and extended (beyond 3-6 months). ...Better prediction tools for major hemorrhage are needed. Experience with new ora …
OBJECTIVE: To review the etiology of VTE and the 3 phases of VTE treatment: acute (first 5-10 days), long-term (from end of acute tre …
Heparin-induced osteoporosis and pregnancy.
Le Templier G, Rodger MA. Le Templier G, et al. Among authors: rodger ma. Curr Opin Pulm Med. 2008 Sep;14(5):403-7. doi: 10.1097/MCP.0b013e3283061191. Curr Opin Pulm Med. 2008. PMID: 18664969 Review.
PURPOSE OF REVIEW: Osteoporosis is the most common serious side effect of long-term unfractionated heparin use. Until recently, it was unknown whether long-term low-molecular-weight heparin was associated with any change in bone mineral density. With increasing long …
PURPOSE OF REVIEW: Osteoporosis is the most common serious side effect of long-term unfractionated heparin use. Until recently, it wa …
Indefinite Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Cost-Effectiveness Study.
Khan F, Coyle D, Thavorn K, van Katwyk S, Tritschler T, Hutton B, Le Gal G, Rodger MA, Fergusson DA. Khan F, et al. Among authors: rodger ma. Ann Intern Med. 2023 Jul;176(7):949-960. doi: 10.7326/M22-3559. Epub 2023 Jun 27. Ann Intern Med. 2023. PMID: 37364263
DATA SOURCES: Systematic reviews and meta-analyses for the long-term risks and case-fatality rates of recurrent VTE and major bleeding. ...
DATA SOURCES: Systematic reviews and meta-analyses for the long-term risks and case-fatality rates of recurrent VTE and major bleedin …
Preventing postpartum venous thromboembolism: A call to action to reduce undue maternal morbidity and mortality.
Andrew L, Ní Áinle F, Blondon M, Rodger MA, Skeith L. Andrew L, et al. Among authors: rodger ma. Thromb Res. 2020 Sep;193:190-197. doi: 10.1016/j.thromres.2020.07.007. Epub 2020 Jul 7. Thromb Res. 2020. PMID: 32738644 Review.
Postpartum venous thromboembolism (VTE) is a leading cause of maternal mortality in developed countries and can carry significant long-term morbidity. Despite being able to identify postpartum VTE risk factors in a large proportion of the obstetrical population, there is l …
Postpartum venous thromboembolism (VTE) is a leading cause of maternal mortality in developed countries and can carry significant long-te …
Management of suspected and confirmed recurrent venous thrombosis while on anticoagulant therapy. What next?
Rodger MA, Miranda S, Delluc A, Carrier M. Rodger MA, et al. Thromb Res. 2019 Aug;180:105-109. doi: 10.1016/j.thromres.2019.06.017. Epub 2019 Jun 26. Thromb Res. 2019. PMID: 31279158 Free article. Review.
As such, we must consider underlying causes of therapeutic failures including malignancy and potent thrombophilias. Finally, short term anticoagulant management of therapeutic failures is controversial, and requires further research, but the best current evidence supports …
As such, we must consider underlying causes of therapeutic failures including malignancy and potent thrombophilias. Finally, short term …
43 results